NASDAQ STOCK MARKET

More news
Celera, Quest Diagnostics Merger

Celera Stock Hits New High On Quest Diagnostics Merger

Shares of Celera Corp. (NASDAQ: CRA) touched a new 52-week high of $8.42 on Friday, as it agreed to be acquired by Quest Diagnostics Inc. (NYSE: DGX) for $8 a share or about $344 million in cash, net of $327 million in acquired cash and short-term investments.
IBTimes Logo

Princeton Review Shares Hit New Low On Q4 Results

Shares of Princeton Review Inc. (REVU) touched a new 52-week low of $0.49 on Thursday, after reporting a wider-than-expected fourth quarter loss. The company also said it has has appointed John Connolly as interim president and chief executive officer, succeeding Michael Perik who has resigned to pursue other interests.
IBTimes Logo

RC2 Shares Hit New High On Tomy Merger

Shares of RC2 Corp. (RCRC) touched a new more than 3-year high of $27.59 on Thursday, shortly after the Nikkei business daily first reported that Japan's Tomy Co. Ltd. and RC2 were in merger talks.
Spectrum Pharmaceuticals

Spectrum Pharma Shares Hit New High on Q4 Results

Shares of Spectrum Pharmaceuticals, Inc. (SPPI) touched a new 52-week high of $7.60 on Thursday. The company posted a decline in fourth quarter earnings as last year period recorded stock warrant gains, but came ahead of Street view.
IBTimes Logo

Focus Media Shares Hit New High On Q4 Results

Shares of Focus Media Holding Ltd. (FMCN) touched a new 52-week high of $30.27 on Wednesday. The company reported Tuesday higher fourth quarter adjusted earnings as revenue in LCD display (including the movie theater network), in-store and poster frame business increased 45 percent.
A sign marks the headquarters of Genzyme in Cambridge

Genzyme Shares Hit New High Again

Genzyme Corp. (NASDAQ: GENZ) said Monday that its board has unanimously recommended to its shareholders to accept the latest sweetened offer from French drug giant Sanofi-Aventis SA (NYSE: SNY) and to tender their shares into the revised offer. The shares of Genzyme touched a new 52-week high of $76.09 on Wednesday.
IBTimes Logo

Velti Initiated At 'Buy': Jefferies

Jefferies & Co. initiated its rating on shares of Velti Plc (NASDAQ: VELT) with a buy rating and a price target of $16.50. The company's unique advantage is that it offers customers the ability to deploy mobile marketing campaigns on a global basis, the brokerage said.
IBTimes Logo

Talecris Biotherapeutics Shares Hit New High

Shares of Talecris Biotherapeutics Holdings Corp. (NASDAQ: TLCR) touched a new 52-week high of $25.80 on Tuesday. The biotechnology company's stock has been rising since Thursday when it received orphan drug designation from the European Commission for the development of Plasmin, derived from human plasma, to treat acute peripheral arterial occlusion.
Starbucks

Single Serve Coffee Is a Good Bet for Starbucks

Single serve coffee represents a meaningful opportunity for Starbucks Corp. (NASDAQ: SBUX) as it is a $4 billion a year market globally with US growing rapidly from its current base of about $100 million, according to RBC Capital Markets.
IBTimes Logo

Xyratex's Hard Disk Drive Segment Under Pressure: Analyst

Xyratex Ltd.'s (NASDAQ: XRTX) hard disk drive-related business segment Storage Infrastructure is currently under pressure from continued, weak demand and excess supply for 2.5-inch (i.e. notebook) drives, according to RBC Capital Markets.
A sign marks the headquarters of Genzyme in Cambridge

Genzyme Shares Hit New High as Board Recommends Sanofi's Revised Offer

Shares of Genzyme Corp. (NASDAQ: GENZ) touched a new 52-week high of $75.90 on Monday. The biotechnology firm's board has unanimously recommended to its shareholders to accept the latest sweetened offer from French drug giant Sanofi-Aventis SA (NYSE: SNY) and to tender their shares into the revised offer.

Pages

IBT Spotlight

We Help Businesses Find B2B Service Providers They Can Trust.